Literature DB >> 6423314

Treatment of chronic idiopathic urticaria with terfenadine.

R Cerio, M H Lessof.   

Abstract

The usefulness of antihistamines is impaired by their sedative side effects. In a double blind crossover study of twenty-four patients with chronic idiopathic urticaria, we have found terfenadine to be a non-sedative and highly effective drug.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6423314     DOI: 10.1111/j.1365-2222.1984.tb02644.x

Source DB:  PubMed          Journal:  Clin Allergy        ISSN: 0009-9090


  8 in total

1.  WONCA 1986: A Personal Impression.

Authors:  J Wilbush
Journal:  Can Fam Physician       Date:  1986-07       Impact factor: 3.275

2.  Newer non-sedating antihistamines. Will they replace older agents?

Authors:  M L Brandon
Journal:  Drugs       Date:  1985-11       Impact factor: 9.546

Review 3.  Terfenadine. The first nonsedating antihistamine.

Authors:  H C Masheter
Journal:  Clin Rev Allergy       Date:  1993

Review 4.  Histamine2 (H2)-receptor antagonists in the treatment of urticaria.

Authors:  T C Theoharides
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

5.  Failure of terfenadine as an antipruritic agent in atopic dogs: results of a double-blinded, placebo-controlled study.

Authors:  D W Scott; W H Miller; S M Cayatte; G A Decker
Journal:  Can Vet J       Date:  1994-05       Impact factor: 1.008

Review 6.  Terfenadine. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  E M Sorkin; R C Heel
Journal:  Drugs       Date:  1985-01       Impact factor: 9.546

Review 7.  Terfenadine. An updated review of its pharmacological properties and therapeutic efficacy.

Authors:  D McTavish; K L Goa; M Ferrill
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

8.  Terfenadine and placebo compared in the treatment of chronic idiopathic urticaria: a randomised double-blind study.

Authors:  J Ferguson; K J MacDonald; K J Kenicer
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.